COAG Stock — Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. (COAG)

Updated October 16, 2026.

COAG is a Stock. Total return is 67.1% over the past 0.5 years, 60.4 points ahead of SPY at 6.7%.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing bispecific and monovalent antibodies to treat blood coagulation disorders, including therapies in Phase 1/2 and Phase 2 clinical development for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand disease. The company does not currently have an established distribution schedule. This security may appeal to investors with a high risk tolerance seeking exposure to early-stage biotechnology development.

COAG performance versus SPY

Price and return data through 2026-10-16.

Total return is 67.1% over the past 0.5 years, 60.4 points ahead of SPY at 6.7%.

COAG key facts

Asset type

Stock

Asset class

Equity

Inception date

04/30/2026

Distribution frequency

None

Last close

$30.07 (as of 2026-10-16)

Market cap

$1,404,633,358

Average volume

351800.0

Payout ratio

0.0%

EPS

$-4.33

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

Who may consider COAG — and who may not

It is a weaker fit for investors who need monthly cash flow (COAG does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on COAG

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions